Loading...
Loading...
SNDX| Name | Value |
|---|---|
| Revenues | 3.5M |
| Cost of Revenue | 44.3M |
| Gross Profit | -40.8M |
| Operating Expense | 77.7M |
| Operating I/L | -74.2M |
| Other Income/Expense | 6.2M |
| Interest Income | 6.3M |
| Pretax | -68.1M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | -68.1M |
Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company specializing in developing innovative cancer therapies. Its lead product candidates include SNDX-5613, targeting MLL-rearranged and NPM1c AML, and SNDX-6352 (axatilimab), designed for chronic graft versus host disease (cGVHD) patients. The company also focuses on the development of Entinostat. Syndax Pharmaceuticals generates revenue through the advancement of its clinical-stage product candidates, as well as through collaborative research and development agreements with organizations such as the National Cancer Institute and Eastern Cooperative Oncology Group, and a license agreement with Kyowa Hakko Kirin Co., Ltd.
